Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 6/20 | 0.35 |
| ▸ | HTR2C | P28335 | 6/20 | 0.35 |
| ▸ | HTR2B | P41595 | 6/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532890 | 0.79 | GRIN2B (0.40) | GRIN2BCYP3A4SCN9AALDH1A1MAPT | |
| SCHEMBL13326519 | 0.73 | CYP3A4 (0.47) | GRIN2BCHRM2CHRM1CHRM3CYP3A4 | |
| SCHEMBL12806994 | 0.70 | GRIN2B (0.46) | GRIN2BCHRM2CHRM1CHRM3CYP3A4 | |
| SCHEMBL4573023 | 0.67 | CHRM2 (0.37) | HTR2AHTR2CHTR2BCHRM2CHRM1 | |
| Bromide SCHEMBL4573068 | 0.66 | CHRM2 (0.36) | HTR2AHTR2CHTR2BCHRM2CHRM1 | |
| SCHEMBL13534528 | 0.65 | IRAK4 (0.32) | HTR2AHTR2CHTR2BCHRM2CHRM1 | |
| SCHEMBL13532907 | 0.65 | IRAK4 (0.32) | HTR2AHTR2CHTR2BCHRM2CHRM1 | |
| SCHEMBL22644735 | 0.64 | HTR6 (0.37) | HTR2C | |
| SCHEMBL4662664 | 0.64 | HTR6 (0.37) | HTR2C | |
| SCHEMBL27088521 | 0.64 | HTR6 (0.37) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310395-B1 | 9-SUBSTITUTED-B-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | VETOQUINOL SA (FR) | 2012-01-18 | — | — | EP | disclosed |
| US-8071590-B2 | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials | VETOQUINOL SA (FR) | 2011-12-06 | — | — | US | disclosed |
| US-8071590-B2 | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials | VETOQUINOL SA (FR) | 2011-12-06 | — | — | US | disclosed |
| WO-2010004394-A1 | 9-SUBSTITUTED-B-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | VETOQUINOL SA (FR) | 2010-01-14 | — | — | WO | disclosed |
| US-20100009980-A1 | NOVEL 9-SUBSTITUTED-5-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | VETOQUINOL SA (FR) | 2010-01-14 | — | — | US | disclosed |
| US-20100009980-A1 | NOVEL 9-SUBSTITUTED-5-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | VETOQUINOL SA (FR) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009980-A1 | NOVEL 9-SUBSTITUTED-5-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | Q6ZSR9, NQO2, RECQL | GRIN2B 2552/4885HTR2A 4321/4885HTR2C 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.